NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
ObjectiveTo compare the efficacy and safety of direct switch from levodopa/benserazide (LB) to levodopa/carbidopa/entacapone (LCE) versus LB plus pramipexole (PPX) in Chinese patients with Parkinson's disease (PD) experiencing wearing off (WO).MethodsIn this multicenter, prospective, randomized, open-label, observational study, 140 patients with PD experiencing WO who had been on stable LB treatment were enrolled and randomized 3:2 to receive LCE (84) or LB + PPX (56) treatment for 8 weeks. The primary endpoint was change in the daily "OFF" time from baseline. Change in the daily "ON" time was also assessed. Treatment-emergent adverse events (TEAEs) were recorded.ResultsSeventy-nine patients in the LCE group and 49 patients in the PPX group completed the study. Both LCE and PPX shortened the patients' daily OFF time significantly after 8 weeks (-1.76 ± 1.70 h, p p p = 0.414). Correspondingly, both the LCE group and the PPX group had significantly increased daily ON time (1.62 ± 1.59 h, p p p = 0.412). Both treatments improved the patients' WO symptoms, sleep quality, depression and quality of life. Six (7.59%) patients in the LCE group and 7 (14.29%) patients in the PPX group reported TEAEs, all of which were mild and tolerable. One patient in the LCE group and 2 patients in the PPX group experienced mild dyskinesia.ConclusionLCE and LB + PPX were both effective, safe and tolerable in treating patients with PD who experienced WO.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.